Skip to main content
    K

    Kiora Pharmaceuticals Inc (KPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.98
    -0.25 (-20.16%)

    Market Cap: $5.44M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Kiora Pharmaceuticals Inc (KPRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Kiora Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$10.84M, operating cash flow was -$9.96M and free cash flow was -$10.07M. The quarter ended Sep 30, 2026 had revenue of $1.00M and net income of -$1.75M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $12.83M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$16.02MN/A100.0%28.2%22.4%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$12.06K-99.6%100.0%-56960.5%-56901.7%
    Dec 2019$2.69M+62.5%100.0%-264.7%-264.2%
    Dec 2018$1.65M+305.5%100.0%-656.3%-654.2%
    Dec 2017$407.52K-39.1%100.0%-3572.7%-3243.5%
    Dec 2016$669.26KN/A100.0%-1994.3%-1993.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$16.02M$0$0$0$12.06K$2.69M$1.65M$407.52K$669.26K
    Gross profit$0$16.02M$0$0$0$12.06K$2.69M$1.65M$407.52K$669.26K
    Research and development$10.78M$7.84M$4.03M$3.45M$5.35M$3.57M$5.39M$8.06M$10.33M$8.42M
    Operating income-$12.83M$4.51M-$12.59M-$12.31M-$14.24M-$6.87M-$7.11M-$10.84M-$14.56M-$13.35M
    Net income-$10.84M$3.59M-$12.51M-$13.58M-$13.77M-$6.86M-$7.10M-$10.81M-$13.22M-$13.34M
    EBITDAN/AN/A-$12.53MN/A-$14.19M-$6.84M-$7.06M-$10.81M-$14.54M-$13.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.00M$0$0$0$0$0$0-$15.95M$0$20.00K$16.00M$283.87K
    Gross profit$1.00M$0$0-$10.51K$0$0$0-$15.99M$0$20.00K$16.00M-$7.93K
    Operating income-$1.69M-$2.21M-$2.51M-$7.31M-$794.44K-$2.40M-$2.33M-$2.56M-$3.60M-$2.54M$13.22M-$2.12M
    Net income-$1.75M-$2.08M-$2.42M-$6.52M$26.81K-$2.15M-$2.19M-$4.22M-$3.41M-$2.22M$13.45M-$2.27M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $164.46K by $8.53M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$24.25M$36.48M$13.71M$18.68M$20.13M$15.30M$10.11M$14.28M$14.31M$9.73M
    Current assets$21.75M$29.71M$4.74M$7.68M$8.99M$1.73M$4.32M$8.48M$8.46M$4.15M
    Cash and equivalents$8.70M$3.79M$2.45M$5.96M$7.85M$1.19M$3.78M$8.00M$7.81M$3.64M
    Total liabilities$8.13M$10.72M$7.60M$7.27M$5.55M$5.57M$3.49M$5.34M$16.23M$10.06M
    Short-term debt$164.46K$23.36K$47.07K$322.38K$0$212.28K$83.93K$4.71K$11.21K$12.64K
    Long-term debtN/AN/AN/AN/AN/A$278.19K$0N/AN/AN/A
    Shareholder equity$16.13M$25.76M$6.11M$11.41M$14.58M$9.73M$6.62M$8.94M-$1.93M-$329.42K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$22.37M$23.78M$21.23M$24.25M$29.86M$31.95M$34.02M$36.48M$38.51M$40.81M$42.44M$13.71M
    Total liabilities$7.08M$6.92M$7.29M$8.13M$7.45M$9.82M$10.32M$10.72M$8.48M$7.71M$7.54M$7.60M
    Cash and equivalents$5.57M$7.08M$10.96M$8.70M$5.51M$1.03M$3.77M$3.79M$5.64M$6.58M$31.28M$2.45M
    Shareholder equity$15.30M$16.86M$13.93M$16.13M$22.41M$22.13M$23.70M$25.76M$30.03M$33.10M$34.90M$6.11M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$9.96M$8.56M-$9.56M-$10.43M-$10.68M-$7.32M-$8.15M-$10.84M-$6.47M-$8.41M
    Capital expenditures$110.79K$6.26K$0$0$63.87K$20.08K$0$20.00K$37.00K$11.00K
    Free cash flow-$10.07M$8.55M-$9.56M-$10.43M-$10.74M-$7.34M-$8.15M-$10.86M-$6.51M-$8.42M
    Dividends paidN/AN/AN/AN/AN/AN/A$7.33KN/AN/AN/A
    Share repurchases$0$1.19M$813.32KN/AN/A$498.69K$97.08KN/AN/A$323.81K
    Investing cash flow$14.43M-$22.66M$0$6.38K-$157.02K-$244.44K$0-$270.00K-$37.00K$174.75K
    Financing cash flow$265.65K$15.50M$5.97M$8.62M$17.58M$5.00M$3.92M$11.30M$10.67M$3.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$557.52K-$1.89M-$3.16M-$2.18M-$1.27M-$3.80M-$2.70M-$2.25M$920.06K-$3.73M$13.62M-$2.58M
    Capital expenditures$355$23.46K$5.02K$78.16K$431$32.20K$0$45.03K$3$51.29K$5$1
    Free cash flow-$557.87K-$1.92M-$3.17M-$2.26M-$1.27M-$3.84M-$2.70M-$2.30M$920.05K-$3.78M$13.62M-$2.58M
    Last 12 quarters

    Frequently Asked Questions About KPRX

    What is Kiora Pharmaceuticals' annual revenue?

    Kiora Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Kiora Pharmaceuticals' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Kiora Pharmaceuticals profitable?

    No. Kiora Pharmaceuticals reported net income of -$10.84M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does KPRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.96M minus capital expenditures of $110.79K produced free cash flow of -$10.07M.

    How much debt does Kiora Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $164.46K and cash and equivalents of $8.70M.